ELLANSÉ™

Why Aesthetic Practitioners Choose ELLANSÉ™

ELLANSÉ™ combines immediate volume from a CMC gel carrier with progressive collagen stimulation from PCL microspheres, offering both instant correction and longer-term tissue remodeling — a combination uncommon among single-product fillers. The CMC gel provides structural correction from the moment of injection, while PCL microspheres stimulate neocollagenesis as they slowly undergo hydrolytic biodegradation. [3][5] HA fillers provide immediate volume but no biostimulation; SCULPTRA® stimulates collagen gradually but without immediate volume. [4][5] ELLANSÉ™ dermal fillers are available in four formulations. Order ELLANSÉ™ at wholesale prices at Med Supply Solutions, or contact the team to confirm local availability, pricing, and professional account requirements. Duration tiering is the second differentiator. The S, M, L, and E variants cover commonly reported durations of approximately 12, 18, 24, and up to 48 months, respectively, allowing practitioners to match longevity to patients' ages, aesthetic goals, lifestyles, and maintenance preferences. [1][2] A patient wanting to assess results before committing to a longer duration may start with ELLANSÉ™ S; ELLANSÉ™ L or E may better serve one with established correction goals and predictable anatomy. No other filler brand structures its product range around this kind of duration choice.

Order ELLANSÉ™ at Wholesale Prices

Med Supply Solutions supplies ELLANSÉ™ to licensed aesthetic professionals. Contact the team to confirm local availability, pricing, documentation, and professional account requirements. Order ELLANSÉ™ online today or register for a wholesale account to access the full S/M/L/E range.

What Is ELLANSÉ™ Used For?

ELLANSÉ™ is indicated for facial line and fold correction, volume restoration, and structural contouring in areas where both immediate correction and long-term collagen support are clinically relevant. Primary treatment areas include nasolabial folds, marionette lines, cheeks, temples, jawline, chin, and dorsal hands. Its biostimulatory PCL profile makes it particularly applicable for age-related midface volume loss, structural facial sagging, and loss of jawline definition. [1][2] ELLANSÉ™ is not recommended for the tear trough, lips, or thin-skin areas over superficial vessels. Because it is not reversible with hyaluronidase, patient selection, anatomical assessment, and injection accuracy carry greater clinical weight than with reversible HA fillers; placement errors cannot be quickly corrected post-procedure.

ELLANSÉ™ Product Range — S, M, L, E

The ELLANSÉ™ range offers four duration variants (S, M, L, E), each sharing the same PCL-in-CMC formulation, with durations calibrated to the microsphere degradation rate.

• ELLANSÉ™ S has a commonly reported duration of approximately 12 months and is well-suited for patients new to the product, those assessing results before committing to longer duration, and cases involving moderate volume loss or initial facial rejuvenation protocols.
• ELLANSÉ™ M is commonly reported as lasting approximately 18 months and is the most widely used variant in clinical practice, supporting general facial volumization and contouring.
• ELLANSÉ™ L offers approximately 24 months of sustained correction for established patients with predictable aesthetic goals and areas requiring longer structural support.
• ELLANSÉ™ E is commonly reported to last up to 48 months and is reserved for deep facial contouring, high-volume areas, and carefully selected patients who understand the clinical implications of a long-acting product. Actual duration may vary by patient, treatment area, and jurisdictional labeling. [4]

All variants contain PCL microspheres suspended in a CMC gel carrier. STAT™ (Synchronized Tissue Augmentation Technology) ensures even microsphere distribution throughout the gel, supporting uniform collagen stimulation and predictable correction across the treatment area.

ELLANSÉ™ Treatment Areas

ELLANSÉ™ is indicated across several facial and body zones where structural volume support and collagen stimulation are the primary clinical objectives. Nasolabial folds and marionette lines are among the most common indications. The cheeks and malar region, temples, jawline, and chin are relevant for facial contouring protocols addressing age-related volume loss and structural sagging. Dorsal hand rejuvenation is an additional area of application where volume loss and skin thinning are the primary concerns. Because ELLANSÉ™ provides both immediate correction and progressive collagen remodeling, it is particularly suited for patients with significant midface volume loss who require visible structural improvement without waiting several months for results — a meaningful clinical distinction from gradual-only biostimulators such as the SCULPTRA® collagen stimulator. ELLANSÉ™ should not be used in the tear trough, lips, or thin-skin areas over superficial vessels, where product persistence and the absence of reversibility increase the clinical risk of complications.

How Long Does ELLANSÉ™ Last?

Commonly reported clinical durations vary by variant: ELLANSÉ™ S, approximately 12 months; M, approximately 18 months; L, approximately 24 months; and E, up to 48 months, with actual duration subject to individual patient factors and local product labeling. The rate of hydrolytic degradation of PCL microspheres determines this range. Slower-degrading microspheres in the L and E variants provide longer collagen stimulation support before full resorption. As PCL microspheres biodegrade, they continue stimulating collagen synthesis; the resulting collagen matrix can persist even after microsphere resorption is complete, contributing to the extended correction timeline. [1][4]

About ELLANSÉ™

ELLANSÉ™ is manufactured by Sinclair Pharma plc, a specialty pharmaceutical company founded in 1971 and headquartered in London, UK. Sinclair developed ELLANSÉ™ and holds the patent on STAT™ technology. The product received CE Mark approval in 2006 and was initially positioned as a long-duration alternative to HA fillers. In 2017, Sinclair was reported to have been acquired by Huadong Medicine, a Chinese pharmaceutical company, with the acquisition noted as expanding the brand's global market presence. [4][5] ELLANSÉ™ is now available in more than 70 countries and is positioned as a premium long-duration PCL biostimulatory filler. It sits alongside RADIESSE® fillers in the biostimulator category, though the two products use different carrier systems and stimulation mechanisms, and alongside Lanluma, another Sinclair-associated PCL collagen stimulator. At the core of every variant is STAT™ (Synchronized Tissue Augmentation Technology), which ensures uniform distribution of PCL microspheres within the CMC carrier, preventing clustering and supporting uniform collagen stimulation throughout the treated area.

ELLANSÉ™ Safety Profile

ELLANSÉ™ requires careful patient selection, thorough anatomical assessment, and informed consent before treatment — particularly given its long-acting nature and the absence of an enzymatic reversal option. Common reactions following injection may include redness, swelling, tenderness, itching, bruising, or numbness at the injection site. These effects are typically localized and self-limiting, commonly resolving within days, though duration can vary by treatment area, injection depth, and individual patient factors. [4] A critical safety distinction is reversibility. ELLANSÉ™ cannot be dissolved with hyaluronidase because PCL microspheres are not enzymatically degradable. Unlike HA fillers, placement errors cannot be quickly corrected post-procedure. This makes thorough patient selection, informed consent, conservative dosing, and accurate placement especially important before treatment, requirements comparable to those for longer-duration biostimulatory categories such as RADIESSE® fillers. ELLANSÉ™ is contraindicated in patients with known hypersensitivity to PCL, CMC, or any formulation component, and should be avoided in pregnancy, breastfeeding, autoimmune conditions, active inflammation, or infection. It is not established for patients under 18. ELLANSÉ™ is not suitable for the tear trough, lips, or thin-skinned areas where product persistence and the absence of reversibility increase the risk of complications. [4]

ELLANSÉ™ Regulatory Status

ELLANSÉ™ is a Class III CE-marked medical device, having received CE Mark approval in 2006. [4] It is available in more than 70 countries globally, with local regulatory approvals, indications, and distribution pathways varying by jurisdiction. ELLANSÉ™ is not FDA-approved for use in the United States — practitioners should verify local regulatory status, approved indications, and authorized distribution channels before ordering or using the product. Sinclair Pharma conducts manufacturing in accordance with ISO 13485 and GMP standards.

Administration Overview

• ELLANSÉ™ is typically placed in the deep dermal or subdermal plane using a cannula or needle, depending on the treatment area and the practitioner's technique.
• The CMC gel carrier provides immediate post-injection volume, while PCL microspheres support progressive collagen stimulation over time.
• Post-injection molding or massage may be used, as appropriate, to distribute the product evenly and support contour smoothness.

FAQs

1. What is ELLANSÉ™, and how is it different from HA fillers?

ELLANSÉ™ is a PCL biostimulatory filler with a CMC gel carrier that combines immediate volume correction with progressive collagen stimulation from PCL microspheres — a combination uncommon among single-product fillers. HA fillers provide volume and are typically reversible with hyaluronidase; they are shorter-lasting. ELLANSÉ™ is not reversible with hyaluronidase, and its commonly reported durations are substantially longer, making it a mechanistically distinct option for practitioners treating age-related volume loss and facial structural change.

2. How long do ELLANSÉ™ results last?

ELLANSÉ™ durations are commonly reported as approximately 12 months for S, 18 months for M, 24 months for L, and up to 48 months for E. Actual duration is determined by the hydrolytic degradation rate of PCL microspheres within each formulation. They may vary by patient and local product labeling.

3. Can ELLANSÉ™ be reversed?

No. ELLANSÉ™ cannot be reversed with hyaluronidase because its PCL microspheres are not enzymatically degradable. This makes patient selection, informed consent, conservative correction, and injection accuracy especially important before treatment.

4. What areas is ELLANSÉ™ not suitable for?

ELLANSÉ™ is not recommended for the tear trough, lips, or thin-skin areas over superficial vessels. These areas carry elevated risk due to tissue sensitivity, vascular proximity, and the product's long-acting duration and non-reversibility — practitioners should assess suitability carefully and obtain informed consent before use.

5. Is ELLANSÉ™ FDA approved?

No. ELLANSÉ™ is a CE-marked medical device available in more than 70 countries, but it is not FDA-approved for use in the United States. Practitioners should verify their local regulatory status and authorized distribution channels before ordering.

6. How does ELLANSÉ™ compare to SCULPTRA®?

Both are biostimulatory products, but their mechanisms and durations differ. SCULPTRA® uses PLLA to stimulate collagen production gradually without an immediate volume effect, with a commonly reported duration of up to 2 years. ELLANSÉ™ combines immediate CMC gel volume with progressive PCL collagen stimulation, with commonly reported durations ranging up to approximately 48 months with the E variant — a meaningful difference for cases requiring both immediate correction and extended longevity.

7. Where can licensed professionals order ELLANSÉ™?

Licensed professionals can order the full ELLANSÉ™ S/M/L/E range at wholesale prices at Med Supply Solutions. Register for an account or contact the team to confirm local availability, documentation, and professional account requirements.

Citations

1. Moers-Carpi MM, Sherwood S. Polycaprolactone for the correction of nasolabial folds: a 24-month, prospective, randomized, controlled clinical trial. Dermatol Surg. 2013;39(3 Pt 1):457-463. doi:1111/dsu. 12054
2. Galadari H, van Abel D, Al Nuami K, Al Faresi F, Galadari I. A randomized, prospective, blinded, split-face, single-center study comparing polycaprolactone to hyaluronic acid for treatment of nasolabial folds. J Cosmet Dermatol. 2015;14(1):27-32. doi:1111jocd. .12126
3. Kim JA, Van Abel D. Neocollagenesis in human tissue injected with a polycaprolactone-based dermal filler. J Cosmet Laser Ther. 2015;17(2):99-101. doi:10.3109/14764172.2014.968586
4. Sinclair Pharma. Ellansé® Summary of Safety and Clinical Performance (SSCP). Sinclair Pharma. https://sinclair.com/media/dzunuwow/e-mdd-sscp-02-ellanse-mdd-sscp_digital-version-copy.pdf
5. Sinclair Pharma. Ellansé. https://sinclair.com/brands/injectables-and-threads/ellanse/

For licensed healthcare professionals only. The content of this page is provided for informational purposes and does not constitute medical advice.